- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07706322
Adapting a Sexual Assault Prevention Intervention for Transgender Undergraduates: A One-Arm Pilot Trial (TEA3)
10. juli 2026 oppdatert av: Sarah Peitzmeier
Adapting a Sexual Assault Prevention Intervention for Transgender Undergraduates
The purpose of this study is to adapt and pilot a sexual assault prevention intervention for transgender and nonbinary (trans) undergraduate students.
Forty percent of trans individuals (i.e., individuals whose gender identity does not align with their sex assigned at birth, inclusive of nonbinary people) are sexually assaulted during their time in college.
Despite the magnitude of this issue, there are no sexual assault prevention interventions that have lowered victimization of trans students.
The Enhanced Assess, Acknowledge, Act (EAAA) intervention is recommended by the Centers for Disease Control and Prevention (CDC) and is the only intervention proven to lower rape victimization by over 50% among cisgender female undergraduates.
However, trans-specific vulnerabilities to violence are not addressed in EAAA, nor in the online adaptation of EAAA recently piloted by the study team called internet-delivered EAAA (IDEA3).
This project will adapt and pilot IDEA3 for trans and nonbinary students to develop one of the first evidence-based sexual assault prevention interventions for trans and nonbinary young adults.
We will adapt IDEA3 for trans students ages 18-25 and test it in an initial group which we will use to make revisions to the program.
Then, we will collect participant survey and focus group data on feasibility and acceptability from 4 more groups of participants, revising the intervention between groups.
Finally, we will collect preliminary data on whether the program increased participants' confidence in their ability to defend themselves.
Studieoversikt
Status
Har ikke rekruttert ennå
Forhold
Intervensjon / Behandling
Studietype
Intervensjonell
Registrering (Antatt)
80
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiekontakt
- Navn: Sarah Peitzmeier, PhD
- Telefonnummer: 301-405-2463
- E-post: speitzme@umd.edu
Studer Kontakt Backup
- Navn: Michelle Choi, MA
- Telefonnummer: 301-405-8740
- E-post: mmchoi@umd.edu
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
Tar imot friske frivillige
Ja
Beskrivelse
Inclusion criteria:
- Participants must be adults ages 18 to 25, AND
- Have a gender identity that differs from their sex assigned at birth (e.g. trans or nonbinary) AND
- Be an undergraduate student AND
- Be available during the program times, AND
- Provide the contact information for another trans or nonbinary undergraduate who they would be willing to participate in the intervention with OR express willingness to being partnered with another trans or nonbinary undergraduate at their university AND
- Have access to and willingness to use the videoconferencing software Zoom for the program AND
- Consent to being recorded while participating.
Exclusion Criteria:
- Participant is less than 18 years of age or older than 25 years of age, OR
- Does not identify as a trans or nonbinary individual, OR
- Is not an undergraduate student, OR
- Is not available during the program times, OR
- Does not provide the contact information for another trans or nonbinary undergraduate student who they would be willing to participate in the intervention with AND does not express a willingness to being partnered with another undergraduate OR
- Does not have access to and or is unwilling to use the videoconferencing software Zoom, OR
- Does not consent to being recorded while participating.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Annen
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: TEA3 Intervention
|
Delivery of TEA3 intervention, a 15-hour online sexual assault resistance intervention for transgender undergraduates.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Intervensjonsdeltakeres selvforsvars selveffektivitet
Tidsramme: Innen en uke etter den siste intervensjonsøkten
|
Dette vil bli vurdert fra deltakersvar til baseline- og post-testundersøkelser som bruker validerte skalaer for å måle selvforsvarseffektivitet (dvs.
tillit til at man kan forsvare seg mot seksuelle overgrep)
|
Innen en uke etter den siste intervensjonsøkten
|
|
Feasibility of TEA3 intervention
Tidsramme: Within one week of the final intervention session
|
This will be assessed by reviewing speed of recruitment and noting no-shows (at first session), overall session attendance, and retention rates for the online intervention to determine whether incentives are sufficient for a future larger trial; reviewing fidelity to the original intervention based on reviewing recordings of all online intervention sessions; reviewing and cataloging deviations from the manual; and final review of what pieces of TEA3 went well and what pieces need to be further adapted in the future.
|
Within one week of the final intervention session
|
|
Acceptability of TEA3 intervention
Tidsramme: Within one week of the final intervention session
|
This will be assessed from summary statistics calculated from survey questions completed by participants relating to dimensions of affective attitude (how the individual feels about the intervention); burden (perceived effort required to participate); ethicality (extent to which the intervention fits with the individual's value system), perceived effectiveness, and whether they would recommend the intervention to a friend.
|
Within one week of the final intervention session
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Efficacy of TEA3 intervention
Tidsramme: Within one week of the final intervention session
|
This will be assessed from participant answers to baseline and post-test surveys that use validated scales to measure five intermediary outcomes that account for EAAA's effect on reducing victimization: earlier detection of risk in coercive situations; greater risk perception of acquaintance rape; lower rape myth acceptance; knowledge of, and willingness to use evidence-based forceful verbal and physical resistance in a hypothetical situation; and earlier identification of 'discomfort' and earlier willingness to leave a hypothetical situation.
The sexual assault victimization outcome measure for a future RCT, a validated trans adaptation of the Sexual Experiences Survey, will also be used.
|
Within one week of the final intervention session
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Etterforskere
- Hovedetterforsker: Sarah Peitzmeier, PhD, University of Maryland, College Park
Publikasjoner og nyttige lenker
Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Antatt)
2. september 2026
Primær fullføring (Antatt)
30. april 2027
Studiet fullført (Antatt)
1. juni 2027
Datoer for studieregistrering
Først innsendt
10. juli 2026
Først innsendt som oppfylte QC-kriteriene
10. juli 2026
Først lagt ut (Faktiske)
15. juli 2026
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
15. juli 2026
Siste oppdatering sendt inn som oppfylte QC-kriteriene
10. juli 2026
Sist bekreftet
1. juli 2026
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- #1670-1
- N/A (Internal grant) (Annet stipend/finansieringsnummer: University of Maryland)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
NEI
IPD-planbeskrivelse
Data from video recordings contain identifiers including participant images and names which cannot be removed, and will therefore remain non-public.
Deidentified survey data from initial screener surveys can be made available upon reasonable request and with IRB approval.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .